comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 16:36:01 - browse：534

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： STAT Summit: Ending the crisis of Black deaths in the U.S.

leisure time

WSS

Gut bacteria may contribute to kidney autoimmunity, study finds

ADCs take center stage as promising cancer treatments

Roivant's CEO is a star, but biotech's black hole persists

STAT Summit: The economic case for universal basic health care

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

UnitedHealth, Optum discontinue NaviHealth name

entertainment

comprehensive

leisure time

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: How researchers deal with rejection

Bright Health sells Medicare Advantage business to Molina

Questions loom on AstraZeneca cancer drug as safety concerns ebb

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Results on Novartis prostate cancer therapy could expand its use

The cancer drug shortage isn’t new — and neither are the solutions

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Trump demands the U.S. pay no more for drugs than other countries … again

Bird flu reported in person exposed to presumably infected cattle

entertainment

How AI can help patients find reliable information about doctors

STAT Summit: How researchers deal with rejection

STAT Summit: The economic case for universal basic health care

The problems with dementia villages

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

STAT Readout: Friday, Oct. 20 biotech updates

leisure time

Wikipedia

explore

entertainment